spacer
The Healthcare Sales & Marketing Network celebrates 25 years serving the medical sales & marketing community.Connecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product LinesConnecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product Lines

Searching News Database:  natalizumab 

 HSMN NewsFeed - 29 May 2018
UCB Announces the Approval of CIMZIA(R) (certolizumab pegol) for Moderate-to-Severe Plaque Psoriasis, Representing an Important New Option for Patients in the U.S.
Biopharmaceuticals Dermatology FDA
 HSMN NewsFeed - 29 Jan 2014
XenoPort Appoints Richard Kim, M.D., as Chief Medical Officer
Biopharmaceuticals Neurology Personnel
 HSMN NewsFeed - 18 Oct 2013
Cimzia(R) (Certolizumab Pegol) Approved by FDA for Treatment of Adults with Active Ankylosing Spondylitis
Biopharmaceuticals FDA
 HSMN NewsFeed - 30 Sep 2013
Cimzia(R) (certolizumab pegol) approved by the U.S. FDA for treatment of adult patients with active psoriatic arthritis
Biopharmaceuticals FDA
 HSMN NewsFeed - 6 Feb 2013
Biogen Idec to Acquire Full Rights and Control of TYSABRI(R) from Elan for Upfront Cash and Contingent Payments
Biopharmaceuticals Neurology Acquisitions
 HSMN NewsFeed - 16 Jan 2013
Biogen Idec and Elan Submit Applications for First-Line Use of TYSABRI in Anti-JCV Antibody Negative Patients with MS
Biopharmaceuticals Neurology
 HSMN NewsFeed - 20 Jan 2012
Quest Diagnostics STRATIFY JCV(TM) First FDA Market Authorized Antibody-based Blood Test to Help Stratify PML Risk in Multiple Sclerosis Patients
Diagnostics Neurology Personalized Medicine FDA
 HSMN NewsFeed - 20 May 2011
European Medicines Agency’s Committee for Medicinal Products for Human Use Issues Positive Opinion on Marketing Authorisation Application for FAMPYRA
Biopharmaceuticals Neurology Regulatory
 HSMN NewsFeed - 16 May 2011
Biogen Idec Receives Approval for FAMPYRA in Australia to Improve Walking Ability in Adult Patients with MS
Biopharmaceuticals Neurology Regulatory
 HSMN NewsFeed - 22 Sep 2010
Biogen Idec Makes Statement About U.S. FDA Approval of Gilenya
Biopharmaceuticals Neurology FDA
 HSMN NewsFeed - 26 Oct 2009
New Data Presented From WELCOME Trial Show Positive Impact of CIMZIA(R) (certolizumab pegol) on Hospitalizations and Surgeries in Patients With Prior Infliximab Failure
Biopharmaceuticals Gastroenterology
 HSMN NewsFeed - 1 Jun 2009
Cimzia(R) (certolizumab pegol) Provides Long-Term Remission and Response Rates in Infliximab-Refractory Crohn's Patients
Biopharmaceuticals Gastroenterology
 HSMN NewsFeed - 13 May 2009
UCB's CIMZIA(R) (certolizumab pegol) Approved by the U.S. FDA for Adult Patients Suffering From Moderate to Severe Rheumatoid Arthritis
Biopharmaceuticals FDA
 HSMN NewsFeed - 9 Feb 2009
MS Patients Treated with TYSABRI Remain Free of Disease Activity for Two Years, According to Data Published in the Lancet Neurology
Biopharmaceuticals Neurology
 HSMN NewsFeed - 18 Sep 2008
New Long-Term Data Show That Patients Taking AVONEX(R) for up to 15 Years Experience Reduced Disability Progression and Improved Quality of Life
Biopharmaceuticals Neurology
 HSMN NewsFeed - 5 Sep 2008
Elan and Biogen Idec Initiate First Clinical Trial of TYSABRI(R) in Oncology
Biopharmaceuticals Oncology
 HSMN NewsFeed - 30 Aug 2008
Monoclonal Antibody Sales to Almost Double in Coming Years
Biopharmaceuticals
 HSMN NewsFeed - 22 Jul 2008
Biogen Idec and Elan Celebrate Second Anniversary of TYSABRI(R) for the Treatment of Multiple Sclerosis
Biopharmaceuticals Neurology
 HSMN NewsFeed - 29 May 2008
Biogen Idec Names Hans Peter Hasler Chief Operating Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 19 May 2008
Biogen Idec Celebrates 30 Years of Transforming Discovery into Care
Biopharmaceuticals
 HSMN NewsFeed - 15 Apr 2008
Biogen Idec and Elan Present New TYSABRI(R) Data at the 60th Annual Meeting of the American Academy of Neurology
Biopharmaceuticals Neurology
 HSMN NewsFeed - 14 Jan 2008
FDA Approves TYSABRI(R) for the Treatment of Moderate-to-Severe Crohn's Disease
Biopharmaceuticals FDA Gastroenterology
 HSMN NewsFeed - 7 Jan 2008
Biogen Idec and Elan Provide Update on Utilization, Safety and Total Patient Exposure of TYSABRI(R) in Patients with Multiple Sclerosis
Biopharmaceuticals Neurology
 HSMN NewsFeed - 25 Oct 2007
New Long-Term Analysis of Clinical Treatment Outcomes Demonstrated COPAXONE(R) is More Cost Effective Than Tysabri(R) for Treatment of Relapsing-Remitting Multiple Sclerosis
Biopharmaceuticals Neurology
 HSMN NewsFeed - 15 Oct 2007
Elan and Biogen Idec Announce That FDA Will Extend Regulatory Review Period for TYSABRI(R) for Crohn's Disease
Biopharmaceuticals Gastroenterology FDA
 HSMN NewsFeed - 11 Oct 2007
Biogen Idec and Elan Provide Update on Utilization and Safety of TYSABRI(R) in Patients with Multiple Sclerosis
Biopharmaceuticals Neurology
 HSMN NewsFeed - 20 Aug 2007
TYSABRI(R) Demonstrates Significant Health-Related Quality-of-Life Improvements for Multiple Sclerosis Patients in Study Published in Annals of Neurology
Biopharmaceuticals Neurology
 HSMN NewsFeed - 31 Jul 2007
Joint FDA Advisory Committee Recommends Approval of TYSABRI(R) for the Treatment of Moderate to Severe Crohn's Disease
Biopharmaceuticals Gastroenterology FDA
 HSMN NewsFeed - 31 Jul 2007
Accentia Biopharmaceuticals Files Pre-Investigational New Drug (IND) Application with FDA for Pivotal Phase 3 Clinical Trial of Revimmune for Refractory Multiple Sclerosis
Biopharmaceuticals Neurology FDA
 HSMN NewsFeed - 23 Jul 2007
TYSABRI(R) Celebrates One-Year Anniversary as a Treatment for Multiple Sclerosis
Biopharmaceuticals Neurology
 HSMN NewsFeed - 19 Jul 2007
Elan and Biogen Idec Preparing to Appeal Ruling on European Application for Natalizumab for the Treatment of Crohn's Disease
Biopharmaceuticals Gastroenterology Regulatory
 HSMN NewsFeed - 18 Jun 2007
Oculus Innovative Sciences Appoints Vice President of Regulatory Affairs and Quality
Biopharmaceuticals Personnel
 HSMN NewsFeed - 29 May 2007
Elan and Biogen Idec Announce a FDA Advisory Committee Meeting to Review TYSABRI(R) for the Treatment of Crohn's Disease
Biopharmacetuicals Gastroenterology FDA
 HSMN NewsFeed - 3 May 2007
Data Presented at the American Academy of Neurology's Annual Meeting Provide Update on Utilization and Safety of TYSABRI(R) in Patients with Multiple Sclerosis
Biopharmaceuticals Neurology
 HSMN NewsFeed - 15 Dec 2006
Elan and Biogen Idec Submit Supplemental Biologics License Application to the FDA for the Approval of TYSABRI(R) as a Treatment for Crohn's Disease
Biopharmaceuticals Gastroenterology FDA
 HSMN NewsFeed - 24 Oct 2006
TYSABRI(R) Maintained Remission in Patients with Moderate-to-Severe Crohn's Disease Treated for Longer Than Two Years According to Data Presented This Week
Biopharmaceuticals Gastroenterology
 HSMN NewsFeed - 6 Oct 2006
New Pharmacoeconomic Data on TYSABRI(R) Demonstrate Significant Reduction in Steroid Use and Hospitalizations in Patients with Multiple Sclerosis
Biopharmaceuticals Neurology
 HSMN NewsFeed - 29 Sep 2006
New Data Presented at ECTRIMS Congress Show TYSABRI(R) Has Sustained Effect on Relapse Rate in Multiple Sclerosis Patients Treated for up to Three Years
Biopharmaceuticals Neurology
 HSMN NewsFeed - 28 Sep 2006
New Data on TYSABRI(R) Presented at ECTRIMS Congress Demonstrate Significant Improvement in Cognitive Function in Patients with Multiple Sclerosis
Biopharmaceuticals Neurology
 HSMN NewsFeed - 24 Jul 2006
Biogen Idec and Elan Announce Availability of TYSABRI(R) for the Treatment of Relapsing Forms of Multiple Sclerosis
Biopharmaceuticals Neurology
 HSMN NewsFeed - 29 Jun 2006
TYSABRI(R) Receives Approval in European Union for the Treatment of Relapsing Remitting Forms of Multiple Sclerosis
Biopharmaceuticals Regulatory Neurology
 HSMN NewsFeed - 5 Jun 2006
FDA Approves the Reintroduction of TYSABRI(R) for the Treatment of Relapsing Forms of Multiple Sclerosis
Biopharmaceuticals FDA Neurology
 HSMN NewsFeed - 28 Apr 2006
CHMP Issues Positive Opinion for TYSABRI(R) as a Treatment for Relapsing-Remitting Multiple Sclerosis
Biopharmaceuticals Neurology Regulatory
 HSMN NewsFeed - 6 Apr 2006
New Data on TYSABRI(R) Demonstrate Significant Effects on Health-Related Quality of Life Measures in Patients with Multiple Sclerosis
Biopharmaceuticals Neurology
 HSMN NewsFeed - 29 Mar 2006
Biogen Idec and Elan Announce Re-Initiation of TYSABRI(R) Clinical Trial Dosing in Multiple Sclerosis
Biopharmaceuticals Neurology
 HSMN NewsFeed - 22 Mar 2006
Biogen Idec and Elan Announce That FDA Will Extend Regulatory Review Period for the Reintroduction of TYSABRI(R) for Multiple Sclerosis
Biopharmaceuticals FDA Neurology
 HSMN NewsFeed - 8 Mar 2006
FDA Advisory Committee Unanimously Recommends Reintroduction of TYSABRI(R) for the Treatment of Relapsing Forms of Multiple Sclerosis
Biopharmaceuticals Neurology FDA
 HSMN NewsFeed - 1 Mar 2006
TYSABRI(R) Two-Year Phase III Multiple Sclerosis Clinical Trial Results and Safety Evaluation Published in New England Journal of Medicine
Biopharmaceuticals Neurology
 HSMN NewsFeed - 23 Jan 2006
Biogen Idec and Elan Announce Notification of FDA Advisory Committee Meeting to Review TYSABRI(R) for the Treatment of Multiple Sclerosis
Biopharmaceuticals FDA Neurology
Return to NewsFeed  

 Additional items found! 29

Members: click here for search results from The HSMN Archive (password required)
Members Archive contains 29 additional stories matching:
natalizumab
(Password required)
FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.